Market Research Logo

Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Global Forecast and Analysis 2019-2023

Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Global Forecast and Analysis 2019-2023

Global Anti-CD20 Monoclonal Antibodies (mABs) Market: About this market

Technavio’s anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. Our analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, our global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.

Global Anti-CD20 Monoclonal Antibodies (mABs) Market: Overview

High target affinity and specificity of anti-CD20 mABs

Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.

Development of CD20 bispecific antibodies

The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global anti-CD20 monoclonal antibodies (mABs) market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.

Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Product overview
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Oncology - Market size and forecast 2018-2023
      • Table Oncology - Market size and forecast 2018-2023 ($ millions)
      • Table Approved mAbs for cancer indications
      • Table Oncology - Year-over-year growth 2019-2023 (%)
    • Neurology - Market size and forecast 2018-2023
      • Table Neurology - Market size and forecast 2018-2023 ($ millions)
      • Table Neurology - Year-over-year growth 2019-2023 (%)
    • Immunology - Market size and forecast 2018-2023
      • Table Immunology - Market size and forecast 2018-2023 ($ millions)
      • Table Immunology - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table Some of the approved anti-CD20 mAbs in US
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Some of the approved anti-CD20 mAbs in Europe
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision Framework
  • Drivers and challenges
    • Market drivers
      • Table Some of the major combination therapies for anti-CD20 mAbs
    • Market challenges
      • Table Serious side effects of anti-CD20 mAbs
      • Table Effect on RITUXAN sales after the launch of biosimilars
      • Table Some of the recently approved rituximab biosimilars
      • Table Impact of drivers and challenges
  • Market trends
    • Increasing awareness about therapeutic areas
    • Presence of reimbursement and patient assistance programs
    • Development of CD20 bispecific antibodies
      • Table Some of the CD20 bispecific antibodies under development
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Amgen Inc.
      • Table Amgen Inc. - Vendor overview
      • Table Amgen Inc. - Business segments
      • Table Amgen Inc. - Organizational developments
      • Table Amgen Inc. - Geographic focus
      • Table Amgen Inc. - Key offerings
      • Table Amgen Inc. - Key customers
    • Celltrion Inc.
      • Table Celltrion Inc. - Vendor overview
      • Table Celltrion Inc. - Product segments
      • Table Celltrion Inc. - Organizational developments
      • Table Celltrion Inc. - Geographic focus
      • Table Celltrion Inc. - Segment focus
      • Table Celltrion Inc. - Key offerings
      • Table Celltrion Inc. - Key customers
    • F. Hoffmann-La Roche Ltd.
      • Table F. Hoffmann-La Roche Ltd. - Vendor overview
      • Table F. Hoffmann-La Roche Ltd. - Business segments
      • Table F. Hoffmann-La Roche Ltd. - Organizational developments
      • Table F. Hoffmann-La Roche Ltd. - Geographic focus
      • Table F. Hoffmann-La Roche Ltd. - Segment focus
      • Table F. Hoffmann-La Roche Ltd. - Key offerings
      • Table F. Hoffmann-La Roche Ltd. - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Business segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook